Topic:

Regulatory

Latest Headlines

Latest Headlines

NAFTA says FDA was in its rights to ban Apotex plants

It's tough luck for Canada's Apotex in its international slug fest with the FDA. An arbitration panel has tossed its claim that the FDA violated the North American Free Trade Act when it banned products from its plants in Toronto and Quebec from 2009 to 2011.

J&J's DePuy Synthes unit slapped with FDA Class I recall for jaw-stabilizing device

Johnson & Johnson's DePuy Synthes unit is facing regulators' ire as the FDA slapped the company's recall of its jaw-stabilizing device with a Class I label, its most serious designation.

Fresenius Kabi receives FDA approval of three-chamber bag for parenteral nutrition

Fresenius Kabi announced Aug. 26 that it has received approval of the Kabiven and Perikabiven, parenteral nutrition products in a three-chamber bag.

PharmaJet secures FDA approval for jet injection system for flu vaccine

The FDA has approved the first needle-free delivery system for the inactivated flu vaccine. The jet injector, made by Pennsylvania-based PharmaJet, has been shown to successfully provide vaccination without a needle jab, which could ultimately help improve vaccination rates.

Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C

Want a window into the future of hepatitis C drug marketing? Keep an eye on Europe. Bristol-Myers Squibb bagged European approval for its hepatitis C fighter Daklinza (daclatasvir) Wednesday, setting the company up for head-to-head competition with Gilead Sciences' upcoming combo drug.

Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C

Bristol-Myers Squibb bagged European approval for its hepatitis C fighter Daklinza (daclatasvir) Wednesday, setting the company up for head-to-head competition with Gilead Sciences' upcoming combo drug.

FDA approves next-generation Medtronic pacemaker

Medtronic snagged FDA approval for its next-generation cardiac resynchronization therapy (CRT) pacemaker in patients with heart failure, expanding its cardiovascular portfolio and advancing its proprietary technology for heart rhythm therapy.

Alexion gets new Form 483 in follow-up inspection

Despite the best efforts of Alexion, the FDA has lingering concerns about manufacturing of the drugmaker's orphan drug Soliris at a plant in Rhode Island and presented it with a Form 483 with new observations following a follow-up inspection of the plant last week.

Sources: Ranbaxy's manufacturing problems lead to Texas

Ranbaxy Laboratories last year agreed to pay $500 million to settle litigation with federal authorities over the years that the drugmaker failed to follow good manufacturing practices and sold inferior drugs to the U.S. Now sources say it may ante up a much smaller payment to the state of Texas for many of the same issues.

Mad at NICE's cancer drug rejections? Look to drugmakers, agency chief says

Political shilly-shallying about the cost of drugs has to end, the chief of the U.K.'s cost-effectiveness agency says. Government officials and politicians need to be up front with the public about one stark fact: The country's health service just can't afford every drug that can help patients.